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OxBu efficacy was superior to equimolar 5-fluorouracil solu-
tion, and thus the drug should be subjected to the next step 
in preclinical evaluation.  © 2014 S. Karger AG, Basel
 Introduction
 Actinic keratosis is the carcinoma in situ of cutaneous 
squamous cell carcinoma (cSCC), a non-melanoma skin 
cancer (NMSC). Being associated with a papillomavirus 
infection and frequent exposure to the sun, prevalence is 
6–25% in western populations and up to 60% in Australia 
 [1] . Up to 20% of untreated actinic keratosis lesions de-
velop into malignant cSCC, and up to 82% of invasive 
cSCC arise close to actinic keratosis lesions  [2] . Since the 
prediction of carcinoma transformation to the invasive 
disease is not feasible, elimination of the lesions by field 
pharmacotherapy in the premalignant actinic keratosis 
stage is highly recommended  [3] . Yet, current treatment 
options are either not sufficiently effective or very painful 
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 Abstract
 Actinic keratosis, a frequent carcinoma in situ of non-mela-
noma skin cancer (NMSC), can transform into life-threaten-
ing cutaneous squamous cell carcinoma. Current treatment 
is limited due to low complete clearance rates and asks for 
novel therapeutic concepts; the novel purine nucleotide an-
alogue OxBu may be an option. In order to enhance skin pen-
etration, solid lipid nanoparticles (SLN, 136–156 nm) were 
produced with an OxBu entrapment efficiency of 96.5 ± 
0.1%. For improved preclinical evaluation, we combined tis-
sue engineering with clinically used keratin-18 quantifica-
tion. Three doses of 10 –3  mol/l OxBu, dissolved in phosphate-
buffered saline as well as loaded to SLN, were effective on 
reconstructed NMSC. Tumour response and apoptosis in-
duction were evaluated by an increase in caspase-cleaved 
fragment of keratin-18, caspase-7 activation as well as by re-
duced expression of matrix metallopeptidase-2 and Ki-67. 
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or both, and thus cSCC has become a most prevalent lethal 
risk factor in heart and kidney transplant recipients  [4] . 
Complete cure rates in large-size clinical studies are less 
than 70% with 5-fluoruracil (5-FU), diclofenac/hyaluron-
ic acid  [3] , imiquimod  [5] and photodynamic therapy us-
ing 5-aminolaevulinic acid followed by red light irradia-
tion. Response rates are up to 91% when using methyl 
5-aminolaevulinate as photosensitizer for minor to mod-
erate lesions  [6] . Although the ingenol mebutate efficacy 
in larger multicentre trials is even lower (34–42%  [7] ), the 
outcome looks promising with respect to the short-course 
treatment. In a 12-month follow-up study of ingenol meb-
utate, sustained clearance was maximally 46%  [8] .
 We addressed the unmet clinical need of effective 
NMSC field therapy by developing a set of DNA poly-
merase inhibitors by molecular modelling and ligand 
docking using antiviral agents as a starting point  [9, 10] . 
Several compounds inhibited the proliferation of SCC 
cell lines clearly more effectively than of normal human 
keratinocytes  [11] . In-depth, preclinical evaluation of the 
most selectively acting compound OxBu was the primary 
goal of the present study. Since the predictive value of 
animal-generated pharmacological data for humans is 
low (70%  [12] ), we decided on an advanced human-cell-
based NMSC model using a set of biomarkers for read-
out. This includes the caspase-cleaved fragment of kera-
tin-18 (ccK18) and total keratin-18 (tK18) being used to 
evaluate drug-induced apoptosis in patients  [13, 14] .
 The second goal of the present study was to investigate 
the potential surplus value of solid lipid nanoparticles 
(SLN) for topical treatment with OxBu. The molecular 
size of the guanosine-analog phosphonate OxBu exceeds 
400 g/mol  [11] which is not optimal for topical therapy 
 [15] , in particular when aiming for the use in hyperkera-
totic skin. Moreover, 5H bond acceptors are at the cutting 
edge of cutaneous absorbability  [16] . Thus, penetration 
enhancement by drug loading to an efficient carrier sys-
tem may be an option. SLN can provide high drug encap-
sulation capacity, protect labile compounds, ensure long-
term physical stability, improve bioavailability  [17] and 
can restrict systemic toxicity through limited access of the 
agent to blood vessels  [18–20] .
 Materials and Methods
 Materials
 OxBu (MW 436.4 g/mol, logP 1.36) was synthesized  [11] by 
Chiracon (Luckenwalde, Germany). 5-FU (MW 130.1 g/mol, logP 
–0.91) and Nile red (MW 318.4 g/mol, logP 3.10) were supplied by 
Sigma-Aldrich (Munich, Germany). OxBu was dissolved in di-
methylsulphoxide (DMSO; BASF, Ludwigshafen, Germany), 5-FU 
in double-distilled water. Stock solutions were diluted with phos-
phate-buffered saline, pH 7.4 (PBS). OxBu SLN were made of 3.5% 
glyceryl behenate (Compritol ®  888 ATO, Gattefossé, Saint-Priest, 
France) and poloxamer 188 (Lutrol ®  F 68; BASF). All other chem-
icals were of the highest purity available.
 Construction and Characterization of the in vitro NMSC 
Model
 Normal fibroblasts and keratinocytes were isolated from hu-
man juvenile foreskin and cultured as described elsewhere  [21] . 
For model building cells were pooled from 3 donors. In vitro or-
ganotypic NMSC constructs were built based on the cSCC model 
described previously  [22] . We adapted keratinocyte, fibroblast and 
tumour cell seeding to grow actinic keratosis like constructs with 
SCC-12 cells (donated by Howard Green, Dana Farber Institute, 
Boston, Mass., USA) forming nests only in the epidermis. The con-
structs were made from human dermal fibroblasts embedded in 
collagen G ( ≥ 95% collagen I; Biochrom, Berlin, Germany) form-
ing the dermis equivalent (1 × 10 6  fibroblasts, 1st to 3rd passage). 
Normal human keratinocytes (2 × 10 6  keratinocytes, 2nd to 3rd 
passage) were seeded onto of the dermal equivalent next day. The 
constructs were cultivated and raised to air-liquid interface on day 
7. Tumour was induced on day 12 by seeding SCC-12 cells (2 × 10 4  
cells, passage <100) onto the construct which was cultivated for 
another 8 days with change of medium 3 times a week ( fig. 1 a). The 
use of deep-well plates (BD Biosciences, Franklin Lakes, N.J., USA) 
ensured sustenance and increased reproducibility.
 The histological quality of the construct on day 20 was evalu-
ated by haematoxylin and eosin staining of 5 μm paraffin-embed-
ded slices. EZ-DeWax TM  solution (BioGenex, San Ramon, Calif., 
USA) was used to remove paraffin (Thermo Scientific, Braun-
schweig, Germany) from slices. To elucidate the tumour localiza-
tion SCC-12 cells were stained with CellTracker TM  Red CMTPX 
(Invitrogen Molecular Probes, Eugene, Oreg., USA) according to 
the manufacturer’s instructions before seeding.
 OxBu Efficacy on the in vitro NMSC Model
 The drug formulations (10 –3  mol/l) were applied (10 μl/cm 2 ) 
on the surface of the NMSC constructs. For a 7-day treatment reg-
imen 3 applications in total were combined with medium changes 
on days 14, 16 and 18 ( fig. 1 a); on day 18, effects were also evalu-
ated following 2 doses. The formulations were OxBu solution, 
OxBu SLN dispersion and 5-FU solution. Unloaded SLN and re-
spective solvents served as control.
 Proliferation, apoptosis and tumour invasion in the NMSC 
model were investigated by immunofluorescence staining accord-
ing to routine histological protocols. Primary antibodies directed 
to proliferation-up-regulated Ki-67, apoptosis-induced caspase-7 
and invasion-facilitating matrix metallopeptidase-2 (MMP-2) 
were used with fluorescence-labelled secondary antibodies. Pri-
mary and secondary antibodies were supplied by Abcam (Cam-
bridge, UK). 4 ′ ,6-Diamidino-2-phenylindole (Dianova, Hamburg, 
Germany) served for nuclei staining. Pictures of immunofluores-
cence staining, taken with a fluorescence microscope (BZ-8000; 
Keyence, Neu-Isenburg, Germany), were analysed in an observer-
blind fashion by at least 3 experienced researchers.
 Apoptosis was quantified by ccK18 release. Culture medium 
(1 ml) was collected repeatedly over time ( fig. 1 a) and centrifuged 
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modes, we combined M30 Apoptosense ®  with an M65 ®  ELISA 
kit, both obtained from Peviva (Bromma, Sweden). Analysis was 
performed according to the manufacturer’s instructions. For dose 
determination, tumour cell cytotoxicity of OxBu was analysed us-
ing the methylthiazolyldiphenyltetrazolium bromide (MTT) dye 
reduction assay for SCC-12 monolayers  [11] .
 SLN Preparation and Characterization
 OxBu SLN were prepared using the hot homogenization meth-
od  [17, 23, 24] with the modification of drug dissolution in DMSO. 
In short, OxBu dissolved in DMSO was mixed with melted glyc-
eryl behenate. The aqueous phase with 2.5% poloxamer 188 was 
added and then dispersed using a rotor-stator mixer for 30 s at 
9,500 rpm. The pre-emulsion was homogenized applying a pres-
sure of 500 bar (EmulsiFlex-C5; Avestin, Ottawa, Ont., Canada) in 
3 homogenization cycles. The product, containing 5% DMSO, was 
collected in silanized glass vials and cooled down in a 15   °   C water 
bath.
 SLN stability was assessed for at least 3 months with respect to 
lipid concentration (2.5, 3.5, 5.0%, w/w, glyceryl behenate) and 
storage temperature (5, 25, 40   °   C). Particle size and size distribution 
(polydispersity index) were determined by photon correlation 
spectroscopy (PCS; Zetasizer Nano ZS, Malvern Instruments, Mal-
vern, UK). Applying laser diffractometry (Mastersizer 2000; Mal-
vern Instruments), LD 95  values were determined, too. 95% of the 
particles were smaller than the stated LD 95  size. To detect drug crys-
tals exceeding 1 μm, light microscopy was used. In addition, scan-
ning electron microscopy (Zeiss DSM 950 microscope; Zeiss, Jena, 
Germany) images were generated to study size and shape of the 
nanocarriers. Parelectric spectroscopy was employed to check for 
free drug molecules in the aqueous phase and to unravel the mode 
of OxBu interaction with the lipid matrix  [23, 25] . The amount of 
OxBu loaded to SLN (drug entrapment efficiency  [17] ) was quanti-
fied from the supernatant of centrifuged nanocarriers (70,000  g , 90 
min) by high-performance liquid chromatography (HPLC).
 Aiming for a ready-to-use formulation, 2 hydrogels were pre-
pared. For the conventional gel (pH 8) OxBu solution (0.1 mol/l in 
NaOH) was added to 250 mg hydroxyethylcellulose (HEC 10,000; 
Hoechst, Frankfurt/Main, Germany), dispersed in 1 g 86% glyc-
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 Fig. 1.  a Procedure outline. NHDF = Normal human dermal fibroblasts; NHK = normal human keratinocytes.
 b Haematoxylin- and eosin-stained cross-section of the full-thickness human skin model with transformed and 
normal keratinocytes side by side; arrows indicate the tumour cells. The inset shows dysplastic tumour cells with 
atypical, enlarged, irregular and hyperchromatic nuclei.  c ,  d NMSC model stained with 4 ′ ,6-diamidino-2-phe-
nylindole (nuclei) and CellTracker Red CMPTX (SCC-12 cells): aerial view of the separated epidermis ( c ) and 
cross-section of the NMSC model ( d ). Constructs with stained SCC-12 cells were not used for OxBu evaluation. 
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SLN, 250 mg HEC 10,000 were dispersed in 1 g 86% glycerol and 
subsequently filled up with OxBu SLN dispersion. Both gels con-
tained OxBu at a concentration of 10 –3  mol/l.
 In order to study the effect of DMSO on skin penetration of an 
SLN-loaded drug, we loaded SLN with the probe Nile red (0.004%) 
using either glyceryl behenate (5 and 10%) without DMSO  [26] or 
glyceryl behenate (5%) with DMSO (5%) for particle formulation 
as described above.  Incorporation of Nile red into the lipid matrix 
was assured by parelectric spectroscopy. The penetration of Nile 
red-loaded SLN was studied in cryoconserved human female skin 
ex vivo (aged 39–54 years, n = 3 donors; with permission) accord-
ing to a validated test protocol  [26, 27] .
 HPLC/OxBu Release
 OxBu concentrations were quantified by HPLC (Merck Hi-
tachi, Tokyo, Japan, equipped with a ternary L-6200 pump, 
 AS-2000A autosampler, D 6000 interface). The stationary phase 
was a Luna Pheny Hexyl 4.6 × 150 mm (5 μm packing) column 
and a 4 × 3 mm guard column (Phenomenex, Aschaffenburg, Ger-
many). The mobile phase was sodium phosphate buffer (pH 7.5, 
25 mmol/l):acetonitrile (77:  23, 1.5 ml/min isocratic flow rate). For 
quantification an L-4000A UV detector (Merck Hitachi) was oper-
ated at 276 nm. The retention time of OxBu was 4.8 min. The 
method was validated referring to ICH Q2B  [28] . Linearity was 
proven for OxBu 5 × 10 –7  to 10 –4  mol/l (r 2  >0.99). The lower limit 
of detection (3 × signal-to-noise ratio) and lower limit of quantifi-
cation (10 × signal-to-noise ratio) were 2 × 10 –7  and 5 × 10 –7  mol/l, 
respectively. Recovery from PBS was 96–102%. Precision of inter- 
and intraday measurements was <7% relative standard deviation.
 The release rates of OxBu from formulations were studied as 
described  [26] , and the rate of OxBu release from formulations was 
calculated based on OxBu amounts in the acceptor fluid according 
to Higuchi  [29] .
 Statistical Analysis
 All experiments were performed at least in duplicate; results 
were expressed as arithmetic mean values ± standard error of the 
mean (SEM). Explorative data analysis was done using the Mann-
Whitney test for OxBu efficacy and the Kruskal-Wallis test for 
OxBu release followed by Dunn’s multiple comparison test. p  ≤ 
0.05 was considered to indicate a statistically significant difference.
 Results and Discussion
 OxBu Efficacy on the in vitro NMSC Model
 Initial studies in monolayer cultures indicated high 
OxBu efficacy and a selective effect on transformed kera-
tinocytes  [11] . The next step in the preclinical OxBu eval-
uation was testing in a disease model. Among organo-
typic human-cell based NMSC models, basically 3 ap-
proaches are competing: the use of patient xenografts, 
tumour cell lines only seeded onto a dermal equivalent 
 [30] and cocultures of human primary normal cells with 
tumour cell lines  [22] . As access to patient xenografts is 
limited, we opted for the coculture model already vali-
dated for preclinical treatment evaluation based on a 
study of photodynamic therapy  [22] . Tissue culturing was 
however modified to reconstruct actinic keratosis. Nor-
mal skin models, built for control, showed a multilayered 
viable epidermis with an intact basal membrane zone and 
regularly distributed fibroblasts in the dermal equivalent. 
Within NMSC constructs SCC-12 nests spread across the 
epidermis ( fig.  1 b–d). SCC-12 cells exhibit a dysplastic 
histology; nuclei are atypical, enlarged, irregular and hy-
perchromatic. Since no tumour cells were found in the 
dermal equivalent, we reconstructed actinic keratosis, the 
carcinoma in situ of invasive and metastatic cSCC. Cell-
Tracker Red CMTPX  [31] proved to be useful to trace 
non-invasively tumour cells over time. To ensure that 
SCC-12 cells keep the fluorescent dye over 9 days, we 
stained SCC-12 monolayers for the same period. Model 
construction, performed according to an in-house stan-
dard operating procedure, was highly reproducible as de-
rived from histology evaluation of 7 batches.
 Considering maximal skin penetration of only a few 
percent  [15] and SCC-12 cell viability reduction to 61 ± 
12% 48 h after OxBu (10 –4  mol/l) application (MTT assay, 
n = 3, mean ± SEM), the effect of OxBu (10 –3  mol/l) on 
reconstructed NMSC was compared to the current first-
line NMSC treatment 5-FU  [10, 11] . The comparator dose 
(5-FU, 10 –3  mol/l) was chosen balancing lower 5-FU po-
tency, IC 50 (5-FU) = 9.8 × 10 –7  mol/l compared to 
IC 50 (OxBu) = 3.7 × 10 –10  mol/l  [11] , in SCC cell monolay-
ers and its physicochemical properties, which should fa-
vour skin penetration.
 Immunofluorescence analysis revealed increased cas-
pase-7 staining for OxBu and 5-FU solution compared to 
the respective solvent controls. The pro-apoptotic effect 
of OxBu slightly surmounted the effect of 5-FU whereas 
(almost) no caspase-7 activity was detected in the solvent 
controls. Cell proliferation (Ki-67 staining) decreased fol-
lowing OxBu and 5-FU application compared to solvent 
controls. Interestingly, only OxBu solution reduced the 
expression of MMP-2, indicating less invasive cancerous 
lesions. Neither solvent controls nor 5-FU solution 
showed this effect ( fig. 2 ).
 Although immunofluorescence analysis allows a de-
tailed histological evaluation, this method entails some 
deficiencies. Samples cannot be taken from the same con-
struct before and after treatment, robustness to experi-
mental conditions is low and quantification is poorly 
standardized. This can be overcome by making use of ker-
atin-18 as biomarker. During apoptosis, e.g. induced by 
chemotherapy, caspases cleave tK18, and ccK18 is re-
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of ccK18 and tK18 in tumour patients exceed those in 
healthy persons  [13, 14, 32, 33] . High ccK18 plasma levels 
are correlated with poor prognoses of epithelial cell-asso-
ciated carcinomas, melanoma and different types of SCC 
 [32–34] . Elevated ccK18/tK18 ratios and elevated ccK18 
release after treatment indicate apoptosis induction and 
tumour response  [13, 14] . To evaluate the fraction of 
apoptosis in our NMSC model, we quantified pre- and 
posttreatment ccK18 ( fig. 2 ) and tK18 (not shown) release 
in medium and calculated the ccK18 increase and ccK18/
tCK18 ratio. This approach follows clinical investigations 
 [14, 32, 35] .
 We observed the highest increase in apoptosis among 
all formulations with OxBu solution (1.60-fold increase, 
p < 0.05). 5-FU (0.93-fold increase) did not enhance 
ccK18 release. Comparing posttreatment ccK18/tK18 ra-
tios, OxBu (0.58) shows a higher ratio than 5-FU (0.49) 
and solvent controls (0.36–0.41). Thus, the antitumour 
effect of OxBu is clearly indicated by both immunofluo-
rescence and ccK18 release.
 In conclusion, combining immunofluorescence stain-
ing of MMP-2, Ki-67 and caspase-7  [22, 30] with ccK18 
release data  [13] for efficacy read-out on NMSC con-
structs can offer an approach to a predictive preclinical 
drug evaluation. To the best of our knowledge, this ap-
proach has not been used before.
 OxBu Solid Lipid Nanoparticles
 Next, we developed OxBu SLN to ensure high drug 
levels in the target layers. Particle sizes of OxBu SLN 
[c(OxBu) = 10 –3  mol/l], composed of glyceryl behenate 
and DMSO, were 136–156 nm (PCS) with narrow size 
distribution (polydispersity index = 0.2) the day after pro-
duction. Scanning electron microscopy demonstrated 
regular shape and relatively homogenous size, too ( ta-
ble 1 ). Particle aggregates or drug crystals were not de-
tected by optical and scanning electron microscopy. Drug 
entrapment efficiency was 96.5 ± 0.1%.
 Parelectric spectroscopy was employed to study OxBu 
interaction with the lipid matrix. The dipole mobility f 0  
remained stable at around 0.4 MHz, the dipole density Δε 
increased from 269 to 468. Thus, OxBu molecules were 
either completely incorporated into the lipid matrix or 
 Fig. 2. OxBu efficacy in the NMSC model. ccK18 release on day 20 
after 3 applications of the test formulations (black columns, 10 –3  
mol/l, 10 μl/cm 2  epidermis) or respective controls (white columns); 
the line at 110 U/l depicts ccK18 release on day 14 before treatment. 
Visual evaluation of immunofluorescence staining was made on 
day 18 after 2 applications of the test formulations or respective 
controls. Strong (+++), moderate (++), weak (+) or missing (–) 
presence of the respective antigen was evaluated in an observer-
blind fashion by at least 3 experienced researchers. Controls were 
PBS for 5-fluorouracil, DMSO-PBS for OxBu and unloaded SLN 
for OxBu SLN. The SLN were made of 3.5% glyceryl behenate and 
5% DMSO. The n-fold increases were calculated as day 20/day 14 
ratios. Constructs were from 3 to 5 batches, mean ± SEM,  *  p < 0.05. 
 Table 1.  Stability of OxBu SLN and unloaded SLN
 Formulation  Scanning electron
 microscope picture 
 LD 95  value, nm 
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 SLN made of 3.5% glyceryl behenate, 5% DMSO and sputtered 
with a gold layer of 45 nm on scanning electron microscope pic-
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free in solution, but not attached to the surface. Yet, al-
most complete drug entrapment and additional parelec-
tric spectroscopy measurements at high frequencies ex-
cluded OxBu molecules free in solution. In contrast to 
OxBu embedded into the lipid matrix, glucocorticoids 
tend to attach to the surface of the lipid matrix of the SLN 
 [36] . The difference can be due to the addition of DMSO 
for OxBu SLN formation.
 OxBu SLN sizes as well as size distributions increased 
concomitantly with higher lipid concentrations [2.5% 
(w/w) glyceryl behenate: 245 nm, 3.5%: 326 nm, 5.0%: 378 
nm; PCS, storage at 5   °   C] within 6 months. Particle ag-
gregation [5% (w/w) glyceryl behenate] occurred due to 
incomplete coverage of lipid particle surface by surfactant 
molecules  [24] , too. Increased storage temperature (25, 
40   °   C) destabilized the OxBu SLN dispersion leading to 
higher nanodispersion viscosity and finally to gelation. 
Physical instability at higher temperature was probably 
due to a decrease in the microviscosity of the surfactant 
and therefore a higher particle diffusion constant. Hence, 
the electrostatic repulsion between the particles can be 
easily overcome resulting in aggregation and gel forma-
tion  [24] . However, the particle size of unloaded SLN re-
mained rather stable at 25   °   C, but OxBu SLN increased to 
325 nm (PCS) with 3.5% glyceryl behenate and to 344 nm 
(PCS) with 2.5% glyceryl behenate.
 To investigate the impact of DMSO on the cutaneous 
penetration of the SLN cargo, we opted for the well-
known dye Nile red instead of OxBu. Since DMSO is 
mandatory for loading OxBu to SLN, we cannot perform 
comparative penetration studies with or without DMSO. 
The penetration enhancer DMSO increased Nile red pen-
etration into viable epidermis 1.7-fold (p = 0.07) when 
added to SLN [5% (w/w) glyceryl behenate]. Nile red pen-
etration from SLN (10%  [36] ) was not significantly differ-
ent (0.92-fold) from SLN (5%).
 In summary, OxBu SLN made of 3.5% (w/w) glyceryl 
behenate and 5% DMSO may have the potential to en-
hance skin penetration  [19, 20] .
 OxBu Release
 For a ready-to-use formulation we embedded OxBu 
SLN into HEC gel (SLN gel) which was generated by a 
single-step procedure, thus avoiding drug dilution. For 
efficient topical therapy the formulation must release 
OxBu sufficiently. OxBu release rates (K values) from 
SLN, gel and SLN gel ( fig. 3 ) were calculated plotting re-
leased drug as described by Higuchi  [29] . The release 
rates of OxBu ranked SLN > gel > SLN gel. The signifi-
cantly prolonged release from SLN gel to SLN (p  ≤ 0.05) 
can be explained by a slow diffusion of OxBu into the ac-
ceptor phase, as particle mobility is restricted by the gel 
matrix. In fact, testing SLN alone, OxBu concentrations 
in the acceptor fluid increased rather rapidly. 90% release 
was obtained after 5 h with the SLN, after 17 h with the 
gel and after 24 h with the SLN gel. The reference solution 
released 90% after 2.6 h. Lag times (time for membrane 
saturation plus time for membrane penetration of the 
drug) were low ( ≤ 0.11 h). High r 2  values (r 2  >0.96) dem-
onstrated data reproducibility. Although SLN gel is the 
most convenient OxBu formulation for the patient, we 
decided for the fluid SLN dispersion to focus on SLN ef-
fects on OxBu efficacy.
 SLN Surplus Value for Topical NMSC Treatment with 
OxBu
 In the NMSC model OxBu SLN activated caspase-7 
and inhibited expression of MMP-2 as well as of Ki-67 
close to OxBu ( fig. 2 ). ccK18 release, although it failed to 
be significant ( fig. 2 ), and ccK18/tK18 ratio (0.76) sub-
stantiate a pro-apoptotic effect of OxBu SLN, too.
 Considering the 1.41-fold increase in ccK18 release, 
SLN are slightly less pro-apoptotic compared to OxBu so-
lution. This is in accordance with the recently published 
improvement of wound healing due to enhanced kerati-
nocyte proliferation and migration  [37, 38] . In actinic 
 Fig. 3. Cumulative amount of OxBu released from SLN dispersion, 
gel (HEC gel) and SLN gel (gel-embedded SLN). Mean ± SEM, 
n = 3, SLN made of 3.5% glyceryl behenate and 5% DMSO. The 
inset shows the OxBu release rate K derived from the Higuchi plot 
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keratosis this might be beneficial with respect to local tol-
erability of topical OxBu treatment.
 In a subsequent study we will compare SLN gel to gel. 
A penetration-enhancing and irritation-limiting effect of 
glycerol  [39] might add to the antitumour effect and im-
prove local tolerability. Although a wide variety of nano-
carriers is currently under investigation  [40] , SLN are 
 favourable due to augmented penetration and proven 
safety.
 Conclusion
 The combination of human cell-based tissue engineer-
ing with clinically used keratin-18 and immunofluores-
cence offers an approach to preclinical evaluation of top-
ical anticancer drugs while potentially reducing animal 
testing. The novel guanosine-analog phosphonate OxBu, 
proving most active in the test, may be an innovative op-
tion for topical NMSC treatment. Topical OxBu formula-
tions, with or without nanoparticles, should be further 
investigated in order to improve current disaffecting 
treatment options for NMSC field cancerization.
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